Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 285 (1), 111-4

Interleukin-6 and alpha-2-macroglobulin Indicate an Acute-Phase State in Alzheimer's Disease Cortices

Affiliations

Interleukin-6 and alpha-2-macroglobulin Indicate an Acute-Phase State in Alzheimer's Disease Cortices

J Bauer et al. FEBS Lett.

Abstract

Recent studies indicated that the formation of a major constituent of Alzheimer's disease (AD) senile plaques, called beta A4-peptide, does not result from normal processing of its precursor, amyloid precursor protein (APP). Since proteolytic cleavage of APP inside its beta A4 sequence was found to be part of APP processing the formation of the beta A4-peptide seems to be prevented under normal conditions. We considered whether in AD one of the endogenous proteinase inhibitors might interfere with APP processing. After we had recently found that cultured human neuronal cells synthesize the most potent of the known human proteinase inhibitors, alpha-2-macroglobulin (alpha 2M), upon stimulation with the inflammatory mediator interleukin-6 (IL-6) we now investigated whether alpha 2M and IL-6 could be detected in AD brains. Here we report that AD cortical senile plaques display strong alpha 2M and IL-6 immunoreactivity while no such immunoreactivity was found in age-matched control brains. Strong perinuclear alpha 2M immunoreactivity in hippocampal CA1 neurons of Alzheimer's disease brains indicates that neuronal cells are the site of alpha 2M synthesis in AD brains. We did not detect elevated IL-6 or alpha 2M levels in the cerebrospinal fluid of AD patients. Our data indicate that a sequence of immunological events which seem to be restricted to the local cortical environment is part of AD pathology.

Similar articles

See all similar articles

Cited by 79 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback